Clement Opoku-Temeng

List of Publications by Year
in descending order

27	1,314	567281 15	526287 27
papers	citations	h-index	g-index

29	29	29	2171
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Innate Host Defense against <i>Klebsiella pneumoniae</i> and the Outlook for Development of Immunotherapies. Journal of Innate Immunity, 2022, 14, 167-181.	3.8	13
2	Targeting Cyclic Dinucleotide Signaling with Small Molecules. , 2020, , 577-591.		2
3	Inhibitors of Intracellular Gram-Positive Bacterial Growth Synthesized via Povarovâ€“Doebner Reactions. ACS Infectious Diseases, 2019, 5, 1820-1830.	3.8	11
4	Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice. EBioMedicine, 2019, 40, 231-239.	6.1	11
5	Proteomic analysis of bacterial response to a 4-hydroxybenzylidene indolinone compound, which re-sensitizes bacteria to traditional antibiotics. Journal of Proteomics, 2019, 202, 103368.	2.4	27
6	Antibacterial Small Molecules That Potently Inhibit Staphylococcus aureus Lipoteichoic Acid Biosynthesis. ChemMedChem, 2019, 14, 1000-1004.	3.2	25
7	Klebsiella pneumoniae capsule polysaccharide as a target for therapeutics and vaccines. Computational and Structural Biotechnology Journal, 2019, 17, 1360-1366.	4.1	60
8	3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties. Bioorganic Chemistry, 2018, 78, 418-426.	4.1	35
9	AlkynylnicotinamideâEBased Compounds as ABL1 Inhibitors with Potent Activities against DrugâEResistant CML Harboring ABL1(T315I) Mutant Kinase. ChemMedChem, 2018, 13, 1172-1180.	3.2	12
10	Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. Future Medicinal Chemistry, 2018, 10, 823-835.	2.3	17
11	Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor. Chemical Communications, 2018, 54, 4521-4524.	4.1	11
12	Suramin potently inhibits cGAMP synthase, cGAS, in THP1 cells to modulate IFN-Î² levels. Future Medicinal Chemistry, 2018, 10, 1301-1317.	2.3	78
13	N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria. European Journal of Medicinal Chemistry, 2018, 155, 797-805.	5.5	34
14	Fluorescent analogs of cyclic and linear dinucleotides as phosphodiesterase and oligoribonuclease activity probes. RSC Advances, 2017, 7, 5421-5426.	3.6	11
15	Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines. Future Medicinal Chemistry, 2017, 9, 1213-1225.	2.3	15
16	Hydroxybenzylidene-indolinones, c-di-AMP synthase inhibitors, have antibacterial and anti-biofilm activities and also re-sensitize resistantÂbacteria to methicillin and vancomycin. RSC Advances, 2017, 7, 8288-8294.	3.6	19
17	Targeting c-di-GMP Signaling, Biofilm Formation, and Bacterial Motility with Small Molecules. Methods in Molecular Biology, 2017, 1657, 419-430.	0.9	28
18	Fluorescent 2-Aminopurine c-di-GMP and GpG Analogs as PDE Probes. Methods in Molecular Biology, 2017, 1657, 245-261.	0.9	1

#	Article	IF	Citations
19	Inhibition of cyclic diadenylate cyclase, DisA, by polyphenols. Scientific Reports, 2016, 6, 25445.	3.3	24
20	Cyclic dinucleotide (c-di-GMP, c-di-AMP, and cGAMP) signalings have come of age to be inhibited by small molecules. Chemical Communications, 2016, 52, 9327-9342.	4.1	78
21	Inhibition of P. aeruginosa c-di-GMP phosphodiesterase RocR and swarming motility by a benzoisothiazolinone derivative. Chemical Science, 2016, 7, 6238-6244.	7.4	39
22	Potent inhibition of cyclic diadenylate monophosphate cyclase by the antiparasitic drug, suramin. Chemical Communications, 2016, 52, 3754-3757.	4.1	19
23	Structureâ€“activity relationship studies of c-di-AMP synthase inhibitor, bromophenol-thiohydantoin. Tetrahedron, 2016, 72, 3554-3558.	1.9	7
24	3-Aminooxazolidinone AHL analogs as hydrolytically-stable quorum sensingagonists in Gram-negative bacteria. MedChemComm, 2015, 6, 1086-1092.	3.4	9
25	Biofilm formation mechanisms and targets for developing antibiofilm agents. Future Medicinal Chemistry, 2015, 7, 493-512.	2.3	492
26	Agents that inhibit bacterial biofilm formation. Future Medicinal Chemistry, 2015, 7, 647-671.	2.3	226
27	Geminal dihalogen isosteric replacement in hydrated AI-2 affords potent quorum sensing modulators. Chemical Communications, 2015, 51, 2617-2620.	4.1	9